Fractyl Health Strengthens Revita Patent Portfolio
Fractyl Health reported the strengthening of its patent portfolio for its Revita DMR system as it progresses toward FDA submission.
Stocks · News reference
8-K filing — FRACTYL HEALTH, INC. (GUTS)
Filed: 2026-10-22 AccNo: 0001193125-26-428302 Size: 238 KB Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Fractyl Health Announces Results of Market Research on GLP-1 Therapy Discontinuation
Fractyl Health released findings from a market survey indicating significant patient interest in a one-time procedural approach for weight maintenance following GLP-1 therapy.
Fractyl Health Announces Strategic Reprioritization and Workforce Reduction
Fractyl Health is sharpening its focus on its lead product candidate, Revita, while discontinuing its Rejuva gene therapy program and reducing its workforce by approximately 45%.
Fractyl Health Names Harith Rajagopalan President
Fractyl Health has appointed Harith Rajagopalan as president following the retirement of Jay Caplan.
Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS
Pomerantz LLP has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) and certain officers for alleged securities fraud. The lawsuit claims Defendants made materially false and misleading statements about the efficacy of Revita, their metabolic therapy device, while conducting public offerings in August-September 2025. On January 29, 2026, Fractyl disclosed disappointing six-month data from the REMAIN-1 Midpoint Cohort showing only 4.5% weight regain versus 7.5% in the sham arm, significantly below expectations. The disclosure revealed operational issues at one clinical site compromised study integrity. Following the announcement, Fractyl's stock price plummeted 68.03% on January 29, 2026, and fell an additional 21.37% on January 30, 2026.